Patients were randomized 1:1:1:1 to receive intravitreal aflibercept 2q8 ( after 3 initial monthly doses ) , intravitreal aflibercept 2q4 , intravitreal aflibercept 0.5 q4 , or ranibizumab 0.5 q4 in the study eye .